Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

Stock Information for Y-mAbs Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Y-mAbs Therapeutics Inc.

Correcting & Replacing - Y-mAbs Provides Strategic Business Update and 2025 Priorities
Y-mAbs Provides Strategic Business Update and 2025 Priorities
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.